117 results about "Cellular infiltration" patented technology

Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey. The tissue engineered scaffolds having a fiber support and honey can further include at least one biomolecule. The tissue engineered scaffolds can be used to promote cellular chemotaxis, enhance cell proliferation, enhance extracellular matrix production, increase angiogenesis, and provide antimicrobial activity. The nature of the tissue engineered scaffolds provides a template for cellular infiltration and guide tissue regeneration. The tissue engineered scaffolds can be used in the treatment of dermal wounds (burns, chronic wounds, etc.) or as a tissue engineering scaffold in a wide range of applications.

The invention belongs to the field of immunological therapy and in particular relates to a transformed hinge region and application thereof in construction of a CAR skeleton. The hinge region providedby the invention can prolong in vivo existence of CAR-T cells and/or improve capability of the CAR-T cells for infiltrating tumors, and an amino acid sequence of the hinge region is shown in SEQ ID NO.1 and SEQ ID NO.2. The hinged region structure provided by the invention can prolong the in vivo existence of the CAR-T cells, a combined chimeric antigen receptor of the hinged region structure canbe more stably expressed in T lymphocytes, CAR-T containing the hinged region provided by the invention is longer in vivo existence, the capability of the cells for infiltrating the tumors is obviously enhanced, and killing effect is better.

The invention relates to bifidobacterium longum capable of relieving atopic dermatitis and application thereof, and belongs to the technical field of microorganisms and the technical field of medicine. Bifidobacterium longum has the effect of relieving atopic dermatitis, and has the advantages that the ear swelling degree of a mouse with atopic dermatitis is remarkably decreased; dermal pathologysymptoms of the mouse with atopic dermatitis are relieved remarkably, and inflammatory cell infiltration is relieved; the serum IgE of the mouse with atopic dermatitis is reduced remarkably; the levelof IL-4 and IL-13 in skin tissue of the mouse with atopic dermatitis is decreased remarkably; the level of histamine in the skin tissue of the mouse with atopic dermatitis is decreased remarkably. Inthis way, bifidobacterium longum has broad application prospects in preparation of products for preventing and/or treating atopic dermatitis.

Disclosed is the use of an adhesion molecule inhibitor that is effective in the prevention and treatment of inflammatory diseases caused by infiltration of leukocytes such as monocytes, lymphocytes and eosindphils, by inhibiting cell infiltration which mediates adhesion molecules, especially adhesion molecule VLA-4.

Since the spiro acid derivatives according to the present invention are excellent in the effect of inhibiting cell adhesion via adhesion molecules, especially adhesion molecule VLA-4, they are useful as therapeutic drugs against various inflammatory diseases. For example, provided are the spiro derivative and the adhesion molecule inhibitor which includes as an active ingredient the spiro derivative as shown by the below formula (18).

Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin α4 chain, e.g., an α4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS.

The invention belongs to the technical field of traditional Chinese medicines and relates to oral liquid for treating chronic atrophic gastritis. The oral liquid is prepared by the following components in parts by weight: 10 parts of Zhejiang white atractylodes rhizome, 15 parts of poria cocos, 10 parts of orange peel, 10 parts of pinellia tenata breit, 10 parts of vinegar rhizoma cyperi, 10 parts of fructus amomi, 10 parts of mangnolia officinalis, 10 parts of vinegar curcuma aromatic, 15 parts of artemisia anomala, 6 parts of cassia twig, 10 parts of rhizoma corydalis, 10 parts of hawthorn, 10 parts of roasted malt, 10 parts of roasted medicated leaven, 10 parts of lindera aggregate, 15 parts of radix paeoniae alba, 12 parts of radix pseudostellariae and 3 parts of liquorice. The oral liquid provided by the invention has the effects of relieving inflammatory cell infiltration, regulating cellular immunity and humoral immunity function, restraining the activity of pepsinogen to promote proliferation and recovery thereof, strengthening barrier protection function of the mucosa, regulating gastrointestinal motility, increasing permeability of gastric mucosa, improving blood circulation of the mucosa, promoting atrophic glands to recover, and delaying or reversing progression of diseases.

The invention belongs to the technical field of pharmacy. According to the application of a protein tyrosine phosphatase SHP2 inhibitor SHP099 in preparation of the medicine for treating psoriasis, aiming at an imiquimod-induced mouse psoriasis-like disease model, the SHP099 can effectively improve epidermal thickening of mouse skin lesion tissues, inflammatory cell infiltration and the level of inflammatory factors in mouse serum. At the cellular level, the SHP099 can significantly reduce the release of inflammatory factors related to psoriasis.

A compound represented by the following general formula (1) or (100), a salt thereof or a hydrate of the foregoing has excellent cell adhesion inhibitory action and cell infiltration inhibitory action.

wherein R¹⁰ represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R³⁰, R³¹ and R³² may be the same or different and each represents hydrogen etc., R⁴⁰ represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X¹ represents CH or nitrogen, and R²⁰, R²¹, R²² and R²³ may be the same or different and each represents hydrogen etc.

The invention relates to a biomarker for gastric cancer diagnosis and treatment and prognosis evaluation, an application of the biomarker and a detection kit. Tumor infiltration immune cytokine IL23Ais used as the biomarker for the gastric cancer diagnosis and treatment and prognosis evaluation, and the relative expression level of the tumor infiltration immune cytokine IL23A is detected to evaluate the prognosis condition of patients. Compared with the prior art, the biomarker provided by the invention has the following advantages: cytokine of the biomarker participates in a plurality of immune response infiltrated by tumor immune cells, can realize the staged development stage of the risk of gastric cancer from a molecular level, rapidly and accurately detect and evaluate the prognosisof the gastric cancer, and effectively improve the sensitivity and specificity of prognosis detection and evaluation of the gastric cancer.

The invention provides an application of a 3-[[2-[3-oxo-(1, 2-benzisoxazole-6-yl) methoxyl]-5-[(2-hydroxyl-4-cyclopentoxyl benzoyl)] phenyl] propionic acid (compound I) in preparation for treatment of connexin CX31 mediated skin disease. The connexin CX31 mediated skin disease comprises erythrokeratodermia variabilis or psoriasis. The pharmacological experiment proves that a low-dose group and a high-dose group of the compound I can remarkably reduce skin damage degree of a psoriasis animal sample; the content of TNF-alpha in murine serum can be restrained by the low-dose group of the compound I, then inflammatory cell infiltration is restrained, the inflammatory response is relieved, and the compound I has good psoriasis treatment effect and can be used for treating the connexin CX31 mediated skin disease.

This invention relates to polysaccharide materials and more particularly to microbial-derived cellulose having the porosity and containing pores of the desired size making it suitable for cellular infiltration during implantation and other desirable properties for medical and surgical applications. The invention also relates to the use of porous microbial-derived cellulose as tissue engineering matrices, human tissue substitutes, and reinforcing scaffolds for regenerating injured tissues and augmenting surgical procedures. The invention outlines various methods during and after fermentation to create porous microbial cellulose capable of allowing cell infiltration while preserving the physical properties of the microbial-cellulose.

Methods of inhibiting inflammation and macrophage infiltration following spinal cord injury and methods of modulating the release of TNF-α from cells expressing α-d are disclosed. Anti-α-d monoclonal antibody was used to block the binding between α-d and VCAM-1. A hybridoma secreting the antibody and a diagnostic method using the antibody are disclosed.

The invention discloses an application of minocycline hydrochloride to preparation of a medicine for treating autoimmune uveitis and a treatment method of the autoimmune uveitis. The inventor finds that the minocycline hydrochloride can be used as an early intervention medicine by exploring the treatment effect of minocycline with different administration dosages on the autoimmune uveitis. By inhibiting microglial cell activation of retina tissue, reducing immune cell infiltration and reconstructing a steady state in gastrointestinal tract flora, generation and development of the uveitis are effectively inhibited, a new application is provided for application of the minocycline hydrochloride, and besides, a new strategy and method are provided for early prevention and intervention of the autoimmune uveitis.

ACE receptors are affected in severe acute respiratory distress syndrome related coronaviruses. ACE genes are directly related to the morbidity and mortality of those with cystic fibrosis. The thick, sticky mucus in the respiratory, and digestive systems, is seen in the inherited disease cystic fibrosis. Viral induced sticky mucus in the respiratory and digestive systems can also be appreciated as a response to viral pathogens where the cycle of mucus production in vivo induces the recruitment of more mucus production to the extent that cellular damage occurs within the lower respiratory track requiring intubation as a life saving measure. In the most severe cases mechanical intubation fails due to the fact that no control over the recruitment of mucus production was achieved at the onset. SARS pathology shows inflammatory exudation in the alveoli and interstitial tissue, with hyperplasia of fibrous tissue and fibrosis. Inherited cystic fibrosis pathology shows atelectasis, mucoid impaction, acute and chronic inflammation, bronchiectasis, cyst formation, and fibrosis widespread. A virally induced disorder in relations to ACE2 receptors can be treated successfully at the early onset with inherited cystic fibrosis disease mimicking techniques with the efforts of minimizing the activity and utilization of the ACE2 receptor. Cystic fibrosis lung infections, and opportunistic pathogens contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release and ceramide accumulation. In terms of virally induced forms off ACE2 receptor pathologies, as it related to coronavirus such as Covid 19, presumably ceramide precursors which aid in intracellular transport of the virus into the cell via inflammation and remodeling is present in alveolar tissues of the lung in patients with cystic fibrosis while the same pathology occurs in patients with virally induced forms of ACE2 pathology which to often progresses to SARS or ARDS.

The invention discloses applications of gene modified mesenchymal stem cell derived microvesicles in preparation of drugs for treating renal injury. Applications of mesenchymal stem cell derived and gene modified miR-34a-MSC-MV, which are specifically designed microvesicles, in preparation of drugs for treating renal injury are included. The level of miR-34a is detected by inducing the overexpression of the miR-34a in MSCs through lentiviral vectors. Through the discovery from pathological observation, the damage level of renal tissue can be obviously improved, renal interstitial fibrosis, lymphocyte infiltration and swelling and necrosis degrees of renal tubules can be obviously alleviated, and renal histopathological scores can be significantly reduced. Through in vivo and in vitro experiments, repair effects of MV and miR-34a-MV are verified; the effects of gene modified stem cells and paracrine products thereof are cleared; and an action mechanism is preliminarily discussed.